GleamWall
中文EN

CRVO CervoMed Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1053691 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-99.9%
TTM net income YoY-11.5%
TTM EPS YoY—
Revenue 3-yr CAGR-87.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-334,924.9%
Net margin-326,822.5%
FCF margin—
EBITDA margin—

Returns

ROE-131.5%
ROA-109.8%
ROIC (approx.)-165.7%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets18.6%
Debt / equity0.00x
Current ratio5.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$8,726$322,569$1.76M$1.92M$2.16M
R&D expense$3.68M$4.32M$5.14M$5.83M$6.04M$5.11M$4.84M$7.09M
SG&A expense$2.43M$2.36M$2.98M$2.51M$2.33M$3.27M$2.38M$2.32M
Operating income-$6.10M-$6.68M-$8.11M-$8.33M-$8.04M-$6.62M-$5.30M-$7.24M
Net income-$5.90M-$6.57M-$7.96M-$8.09M-$7.73M-$6.26M-$4.89M-$6.71M
EPS (basic)-0.39-0.64-0.86—-0.84-0.70-0.56—
EPS (diluted)————————
Balance sheet
Cash & equivalents$6.06M$22.46M$7.94M$8.24M$9.44M$8.32M$10.50M$9.00M
Short-term investments$13.54M$2.48M$4.98M$12.63M$17.86M$25.21M$24.74M$29.92M
Current assets$21.33M$25.99M$15.11M$22.88M$30.61M$38.08M$38.58M$43.08M
Total assets$21.33M$25.99M$15.11M$22.88M$30.61M$38.08M$38.58M$43.08M
Current liabilities$3.97M——$4.66M———$3.88M
Total liabilities$3.97M$3.03M$4.50M$4.66M$4.60M$4.64M$3.94M$3.88M
Shareholders' equity$17.36M$22.96M$10.62M$18.22M$26.01M$33.44M$34.63M$39.20M
Shares outstanding15.12M13.53M9.26M9.25M9.25M9.25M8.70M8.70M
Cash flow statement
Operating cash flow-$5.07M-$6.92M-$8.02M-$6.58M-$6.47M-$6.51M-$3.89M-$8.05M
Investing cash flow-$10.97M$2.53M$7.71M$5.37M$7.58M-$254,993$5.40M$9.31M
Financing cash flow-$357,921$18.91M$13,800$0$0$4.59M$0$0
Stock-based compensation$307,445$362,275$349,196$298,735$291,717$497,015$361,167$337,711

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.